XML 68 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 26, 2018
USD ($)
Jul. 19, 2018
Dec. 22, 2017
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
Jan. 01, 2019
USD ($)
Jan. 01, 2018
USD ($)
Cash Equivalents, at Carrying Value, Total         $ 0 $ 0 $ 0    
Accounts Receivable, Allowance for Credit Loss, Current         0 0 0    
Revenue from Contract with Customer, Excluding Assessed Tax, Total           8,072,120 2,706,981    
Accounts Receivable, after Allowance for Credit Loss, Current, Total         272,557 272,557    
Lease Liability           8,538,337,000      
Retained Earnings (Accumulated Deficit), Ending Balance         (167,053,897) $ (215,239,450) $ (167,053,897) $ (167,655,995)  
Number of Operating Segments           1      
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent     35.00%     21.00% 21.00%    
Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Asset, Income Tax Expense         14,100,000        
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount         (14,100,000) $ 11,178,295      
Series D Preferred Stock [Member]                  
Preferred Stock, Par or Stated Value Per Share | $ / shares           $ 0.001      
Prepaid Expenses and Other Current Assets [Member]                  
Deferred Offering Costs         110,365 $ 0 $ 110,365    
Accounting Standards Update 2016-02 [Member]                  
Right-of-Use Asset               6,400,000  
Lease Liability               9,100,000  
Retained Earnings (Accumulated Deficit), Ending Balance         (602,098)   (602,098) $ (600,000)  
Accounting Standards Update 2014-09 [Member]                  
Retained Earnings (Accumulated Deficit), Ending Balance                 $ (500,000)
GlaxoSmithKline [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax, Total           8,100,000 400,000    
Accounts Receivable, after Allowance for Credit Loss, Current, Total         $ 0 $ 0 $ 0    
Credit Concentration Risk [Member] | Cash Held on Deposit [Member] | Pacific Western Bank [Member]                  
Concentration Risk, Percentage           100.00%      
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member] | GlaxoSmithKline [Member]                  
Concentration Risk, Percentage           100.00% 15.00%    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | GlaxoSmithKline [Member]                  
Concentration Risk, Percentage           0.00% 0.00%    
Reverse Stock Split [Member]                  
Stockholders' Equity Note, Stock Split, Conversion Ratio   16.827              
Pacific Western Bank Note, A&R LSA [Member]                  
Debt Instrument Agreement, Minimum Cash Balance To Be Maintained $ 8,500,000     $ 8,000,000   $ 8,500,000